Key result
Increasing doses of recombinant hirudin as an adjunct to rt-PA in acute myocardial infarction showed a non-significant trend toward greater TIMI 3 flow at 60 min.
Why the study?
Does escalating doses of recombinant hirudin improve early TIMI 3 patency and prevent reocclusion in patients with acute myocardial infarction treated with rt-PA?
Does escalating doses of recombinant hirudin improve early TIMI 3 patency and prevent reocclusion in patients with acute myocardial infarction treated with rt-PA?
In patients with acute myocardial infarction treated with rt-PA, escalating doses of recombinant hirudin showed a non-significant trend toward improved early coronary patency with rare reocclusions.
Answers are grounded in this paper and cite their sources.
Non-significant trend does not support practice change; leaves open whether hirudin dosing improves patency with rt-PA in AMI.
OBJECTIVE: To define an optimal dose of hirudin that would improve early coronary artery Thrombolysis in Myocardial Infarction grade 3 (TIMI 3) patency and prevent reocclusions in patients with acute myocardial infarction treated with front-loaded recombinant tissue-type plasminogen activator (rt-PA). METHODS: Recombinant hirudin (HBW 023) was tested in a sequential dose-escalating study as adjunct to front-loaded rt-PA in 143 patients with acute myocardial infarction. The sequential model was assigned two 'decision boundaries': it triggered an increase in dosage if the 60-min TIMI 3 flow rate in a dosage group was statistically not consistent with a target patency rate of 75%, or if the deterioration in coronary blood flow (of at least one TIMI grade, from TIMI 2 or 3, from one angiography to the next) exceeded 5%. RESULTS: The decision boundary for TIMI 3 flow grade at 60 min was crossed when 18 patients were treated with 0.1/0.06 mg/kg (bolus/infusion per hour over 48 h) r-hirudin (dosage group I), 42 patients treated with 0.2/0.1 mg/kg (dosage group II), and 83 patients with 0.4/0.15 mg/kg (dosage group III). TIMI 3 flow at 60 min was 50%, 58%, and 63% in dosage groups I-III, respectively (P = 0.15). Early, complete, and sustained patency (TIMI 3 flow at 60 min, 90 min and 48 h) were 44%, 55% and 64% (P = 0.07). Reocclusion between 90-min and 48-h angiograms or reinfarction occurred in 0 to 15, two of 36, and one of 72 patients, respectively (P = 0.5). Four patients (2.8%) died in hospital and 14 patients suffered a major bleeding event, but no intracranial bleeding was encountered. CONCLUSIONS: With increasing doses of hirudin, there was a trend towards greater early and complete patency, but no clear dose--response relationship was observed. A borderline significant effect was observed with respect to early, complete, and sustained patencies. In all groups, reocclusions or reinfarctions were rare. Neither clinical nor laboratory data predicted the imbalance in haemorrhagic events observed in a subsequent, prematurely terminated, phase III trial with hirudin and rt-PA.
No takes yet. Share an insight, caveat, or question.
Essen et al. (1998) studied acute myocardial infarction (n=143). Recombinant hirudin (HBW 023) vs. Lower doses of recombinant hirudin was evaluated on TIMI 3 flow grade at 60 min (p=0.15). Increasing doses of recombinant hirudin as an adjunct to rt-PA in acute myocardial infarction showed a non-significant trend toward greater TIMI 3 flow at 60 min.
Synapse has enriched 10 related papers. Consider them for comparative context: